# Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
Canonical URL: https://biopharmsignal.com/news/PRAX/praxis-to-showcase-essential3-the-first-positive-phase-3-program-in-essential-tremor-at-aan-2026
Ticker: PRAX
Company: Praxis Precision Medicines
Source: Praxis Precision Medicines
Published: 2026-04-13 12:00 EST
Original Source URL: https://investors.praxismedicines.com
## Summary

Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis to present 3 oral presentations and 12 posters at AAN 2026 Visit Praxis at Booth #2324 for an

## Article Body
Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026 Praxis to present 3 oral presentations and 12 posters at AAN 2026 Visit Praxis at Booth #2324 for an
## Recent Company News
- 2026-06-01 20:15 EST — [Praxis Precision Medicines Provides Vormatrigine Program Update](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-provides-vormatrigine-program-update) — Source: Praxis Precision Medicines
- 2026-05-07 12:00 EST — [Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-provides-corporate-update-and-reports-first-quarter-2026-financial-results) — Source: Praxis Precision Medicines
- 2026-05-05 20:01 EST — [Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Praxis Precision Medicines
- 2026-05-04 20:01 EST — [Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026-and-participate-in-upcoming-investor-conference) — Source: Praxis Precision Medicines
- 2026-04-14 11:30 EST — [Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor](https://biopharmsignal.com/news/PRAX/praxis-precision-medicines-announces-fda-acceptance-of-new-drug-application-for-ulixacaltamide-hcl-in-patients-with-essential-tremor) — Source: Praxis Precision Medicines
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)